---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-043665"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2023-12-05T23:59:59+00:00"
generated_at: "2026-06-07T18:05:29.691690+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# bioAffinity appoints Jamie Platt to board; Mohsin Meghji resigns

## Summary
- Jamie Platt, Ph.D., appointed to board effective Dec. 1, 2023; also joins Compensation Committee.
- Platt brings 20 years of genomics/diagnostics experience; led two M&A exits worth ~$1B combined.
- Mohsin Meghji resigned same day for personal reasons, no disagreement with company.
- Platt receives standard non-employee director compensation: $25k annual fee + quarterly restricted stock grant valued at $18,750.
- She currently serves as CEO of Pictor Ltd. and President/CEO of BRIDGenomics.

## SEC filing metadata
- accession: 0001493152-23-043665
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2023-12-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000149315223043665/0001493152-23-043665-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000149315223043665/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-043665
- JSON: https://secwatch.observer/filing/0001493152-23-043665.json
- Plain text: https://secwatch.observer/filing/0001493152-23-043665.txt

## Key facts
- Executive change
  Mohsin Y. Meghji resigned as Director at bioAffinity Technologies, Inc..
  - Action: resigned
  - Role: Director
  source text: On December 1, 2023 , Mohsin Y. Meghji resigned from the Board of Directors, effective immediately, for personal reasons, and not due to any disagreement with the Company or its operations, policies or practices.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1712762/000149315223043665/0001493152-23-043665-index.htm
- Executive change
  Jamie Platt was appointed as Director at bioAffinity Technologies, Inc..
  - Action: appointed
  - Role: Director
  source text: On December 1, 2023, the Board of Directors (the “Board”) of bioAffinity Technologies, Inc. (the “Company”) appointed Jamie Platt, Ph.D., to serve as a director of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1712762/000149315223043665/0001493152-23-043665-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.